Profile of:

Pedro Machado

I am an Associate Professor and Consultant Rheumatologist at University College London (UCL). I undertake specialist spondyloarthritis clinics at University College Hospital (UCH) and Northwick Park Hospital, two of the largest hospitals in London, UK. I qualified in Medicine from the University of Coimbra in Portugal and trained in musculoskeletal imaging and clinical epidemiology during my doctoral research at the Leiden University Medical Centre, The Netherlands. I have (co)authored over 190 articles and I have been awarded 4 fellowships and 13 scientific prizes. My research interests include the investigation of new therapeutic strategies and the assessment and prediction of outcomes in rheumatic diseases, with a focus on axial spondyloarthritis (axSpA).

Full name: Pedro Machado

Current country: United Kingdom

Membership level: Full

Type of membership: EC

Number of publications: 29

The ASAS-OMERACT core domain set for axial spondyloarthritis (2021)

Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility (2021)

Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort (2021)

Axial Spondyloarthritis: Mimics and Pitfalls of Imaging Assessment. (2021)

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies (2021)

Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable (2021)

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study (2021)

No relationship between bone mineral density and syndesmophyte formation at the same level in the lumbar spine of patients with radiographic axial Spondyloarthritis (2020)

Long-term association between disease activity and disability in early axial spondyloarthritis: results from the DESIR cohort (2020)

Validity and reliability of a sensor-based electronic spinal mobility index for axial spondyloarthritis (2020)

Determining factors related to impaired spinal and hip mobility in patients with axial spondyloarthritis: longitudinal results from the DESIR cohort (2020)

Recent advances in managing axial spondyloarthritis (2020)

Measuring Spinal Mobility Using an Inertial Measurement Unit System: A Validation Study in Axial Spondyloarthritis (2020)

Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study (2020)

Classification Criteria in Axial Spondyloarthritis: What Have We Learned; Where Are We Going? (2020)

Educational needs in people with ankylosing spondylitis and psoriatic arthritis: a cross-sectional study (2020)

Inhibition of interleukin-17 in axial spondyloarthritis spectrum (2020)

The European Portuguese version of the ASAS Health Index for Patients with Spondyloarthritis: Measurement properties (2020)

Development and validation of psoriatic arthritis switch quality assessment tool (PASQAL) – an outcomes measurement tool to assess the quality of biologic switch decisions in psoriatic arthritis (2020)

Performance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review (2019)

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group (2019)

Recommendations for acquisition and interpretation of MRI of the spine and sacroiliac joints in the diagnosis of axial spondyloarthritis in the UK (2019)

How to investigate: Early axial spondyloarthritis (2019)

Treat-to-target in axial spondyloarthritis: gold standard or fools’ gold? (2019)

Performance of referral strategies for spondyloarthritis: a population-based nationwide study (2019)

Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states (2018)

Biologics for treating axial spondyloarthritis (2018)

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial (2018)

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force (2018)